Pancreatitis (Acute and Chronic) — Clinical Documentation Guide (2026)

🔍 Definition

Pancreatitis is an inflammatory condition of the pancreas characterized by activation of pancreatic enzymes within the gland itself, leading to autodigestion, edema, hemorrhage, and—in severe cases—necrosis. It presents in two clinically distinct forms: acute pancreatitis (AP) and chronic pancreatitis (CP).

Acute pancreatitis is a sudden-onset inflammatory process most commonly triggered by gallstones or alcohol use. The 2012 Revised Atlanta Classification, the international gold standard (Banks et al., Gut 2013), defines three severity tiers: mild (no organ failure, no local/systemic complications), moderately severe (transient organ failure resolving within 48 hours and/or local complications), and severe (persistent organ failure >48 hours, single or multi-organ). Diagnosis requires at least two of three criteria: (1) characteristic abdominal pain, (2) serum lipase or amylase ≥3× upper limit of normal, and (3) confirmatory cross-sectional imaging.

Chronic pancreatitis is a progressive fibro-inflammatory syndrome with irreversible structural changes including fibrosis, ductal strictures, calcifications, and eventual exocrine and endocrine insufficiency. Per the American College of Gastroenterology (ACG), chronic pancreatitis carries significant morbidity due to malnutrition, pancreatic diabetes, and increased risk of pancreatic adenocarcinoma.

Both forms are classified under ICD-10-CM FY2026 Chapter 11 (Diseases of the Digestive System, K00–K95), Section K80–K87 (Disorders of Gallbladder, Biliary Tract, and Pancreas). Acute pancreatitis codes reside in category K85 and chronic pancreatitis in category K86.

🗂️ Alternative Terminology

Coders and CDI specialists encounter a wide variety of clinical terms in provider documentation that map to pancreatitis codes. The table below cross-references common lay and clinical synonyms with their preferred ICD-10-CM classification.

🩺 Signs & Symptoms

Recognition of the clinical presentation is critical for CDI specialists querying providers and for coders validating diagnoses. The table below summarizes key signs and symptoms by acuity.

🧭 Differential Diagnosis

Pancreatitis can mimic—and co-occur with—several serious abdominal conditions. CDI specialists should confirm the definitive diagnosis is clearly documented in the record before coding.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators serve as documentation anchors. Coders should verify these elements are present and clearly documented; CDI specialists should query when indicators are present but diagnosis is unspecified or incomplete.

🦴 Anatomy & Pathophysiology

The pancreas is a retroperitoneal gland approximately 12–15 cm in length, divided into head, neck, body, and tail. It serves dual exocrine (digestive enzyme secretion into the duodenum via the main pancreatic duct of Wirsung) and endocrine (insulin, glucagon, somatostatin secretion from islets of Langerhans) functions. The common bile duct and pancreatic duct typically converge at the ampulla of Vater before emptying into the duodenum, explaining why gallstones can obstruct both structures simultaneously and trigger pancreatitis.

Acute pancreatitis pathophysiology: The initiating event—whether gallstone obstruction, ethanol toxicity, or drug toxicity—causes premature activation of trypsinogen to trypsin within acinar cells. This initiates a cascade of autodigestion: activation of chymotrypsinogen, elastase, phospholipase A2, and complement. Widespread acinar cell injury triggers a local and systemic inflammatory response (cytokine storm: TNF-α, IL-1, IL-6, IL-8), which can progress to SIRS, ARDS, acute kidney injury, and multi-organ failure in severe cases. Necrosis may remain sterile initially but can become infected (most commonly via gut-derived bacteria) within days to weeks, dramatically worsening prognosis and driving MS-DRG tier from DRG 439 to 438.

Chronic pancreatitis pathophysiology: Recurrent episodes of acute inflammation—or chronic low-grade inflammation from ongoing toxin exposure (alcohol, tobacco)—drive progressive pancreatic stellate cell activation, collagen deposition, and irreversible fibrosis. Ductal strictures form, obstructing flow and leading to upstream dilation and stone formation (calcific pancreatitis). Loss of acinar cell mass reduces digestive enzyme output below functional thresholds, causing exocrine pancreatic insufficiency (EPI) with fat malabsorption, steatorrhea, and micronutrient deficiencies (fat-soluble vitamins A, D, E, K). Progressive destruction of islets leads to pancreatogenic (Type 3c) diabetes, which is particularly difficult to manage due to simultaneous loss of glucagon counterregulation.

According to the American College of Physicians and ACG guidelines, the TIGAR-O classification system categorizes chronic pancreatitis etiologies as: Toxic-metabolic (alcohol, tobacco, hypercalcemia, hyperlipidemia), Idiopathic, Genetic (PRSS1, SPINK1, CFTR mutations), Autoimmune, Recurrent acute pancreatitis, and Obstructive.

💊 Medication Impact / Treatment

Understanding treatments documented in the medical record helps coders validate diagnoses and identify additional billable complications or conditions.

Acute pancreatitis management:

• Aggressive IV fluid resuscitation (Lactated Ringer’s preferred over normal saline per WATERFALL trial findings): presence of aggressive IVF in the record supports moderate-to-severe AP documentation
• NPO / enteral nutrition via nasojejunal tube: early enteral feeding within 24–48 hours is now standard for moderate-severe AP; NJ tube placement is a CDI indicator for severity
• Pain management: IV opioids (hydromorphone, morphine, fentanyl); epidural analgesia in severe cases
• Antibiotics (carbapenems, quinolones): only when infected necrosis is confirmed or strongly suspected; antibiotic use in the record is a strong CDI trigger for querying infected vs. uninfected necrosis (K85.x2 vs. K85.x1)
• ICU admission: supports severe AP; multi-organ failure codes should be added
• Interventional procedures: CT-guided or EUS-guided drainage of walled-off necrosis (WON) or pseudocysts; ERCP with sphincterotomy for biliary pancreatitis

Chronic pancreatitis management:

• Pancreatic enzyme replacement therapy (PERT) — pancrelipase (Creon, Zenpep, Viokace): prescribed for documented EPI; PERT initiation is a CDI indicator to ensure K86.81 is coded. FDA-approved pancrelipase products are dosed per meal based on lipase units
• Fat-soluble vitamin supplementation (A, D, E, K): supports malabsorption/malnutrition coding (E63.9 or E46 depending on severity and documentation)
• Analgesics / pregabalin / antidepressants for chronic pain management
• Insulin therapy: when pancreatogenic diabetes (E08.x) is documented, insulin use in the record validates the diagnosis
• Endoscopic therapy (ERCP with stenting, stone extraction, lithotripsy): for ductal strictures and stones
• Surgical options: Puestow (lateral pancreaticojejunostomy), Frey procedure, Whipple (pancreaticoduodenectomy, CPT 48150–48154) for end-stage disease

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines are drawn from the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS/CDC) and relevant AHA Coding Clinic guidance.

Etiology Coding — Acute Pancreatitis (K85)

The 5th character in the K85 code set specifies etiology; the 5th character in the extended code specifies necrosis/infection status. Both dimensions must be documented to select the most specific code:

• K85.0x — Idiopathic: No identifiable cause after workup. Use only when the physician documents idiopathic or unknown etiology after ruling out gallstones, alcohol, and drugs.
• K85.1x — Biliary/gallstone: Requires documented causative relationship between gallstones/choledocholithiasis and acute pancreatitis. The gallstone code (K80.xx) is assigned as an additional code, not the principal diagnosis. Per AHA Coding Clinic, if the patient was admitted primarily for acute pancreatitis caused by gallstones, K85.1x sequences first.
• K85.2x — Alcohol-induced: Requires provider documentation of alcohol as the cause (not merely alcohol use as a comorbidity). Assign F10.xx (alcohol use disorder or dependence) as an additional code per the “use additional code” instruction in Tabular List FY2026.
• K85.3x — Drug-induced: The drug causing the adverse effect must be identified. A T-code from T36–T50 with 7th character ‘A’ (initial), ‘D’ (subsequent), or ‘S’ (sequela) sequences as an additional code. Common offenders include thiazide diuretics, valproic acid, azathioprine, corticosteroids, and some HIV medications.
• K85.8x — Other specified: Covers post-ERCP pancreatitis, hypertriglyceridemia-induced (E78.1 additional), hypercalcemia-induced, trauma-induced, autoimmune, hereditary/genetic forms.
• K85.9x — Unspecified: Use only when the type cannot be determined after review; CDI specialists should query to avoid these codes when possible.

Necrosis Subclassification (5th Character)

• x0 — Without necrosis or infection: Edematous, interstitial pancreatitis; the most common form; DRG 440 (base).
• x1 — With uninfected necrosis: CT/MRI confirms pancreatic or peripancreatic necrosis without evidence of bacterial superinfection; DRG 439 (CC-level).
• x2 — With infected necrosis: Gas within necrotic collection on CT, positive FNA culture, or physician documentation of infected necrosis; DRG 438 (MCC-level, highest reimbursement). This is the most CDI-sensitive character.

Chronic Pancreatitis Guidelines (K86)

• K86.0 — Alcohol-induced: Requires explicit documentation of alcohol as the ongoing etiologic factor. Assign F10.2x (alcohol dependence) as additional code per Tabular instruction.
• K86.1 — Other chronic pancreatitis: Use for autoimmune (Type 1 and Type 2 AIP), hereditary (PRSS1, SPINK1, CFTR mutations), idiopathic, and obstructive chronic pancreatitis. Also use when alcohol is present as a comorbidity but NOT documented as the cause.
• K86.81 — Exocrine pancreatic insufficiency: Assigned in addition to K86.0 or K86.1 per the “Code also” note in the Tabular. Do not assume EPI; it requires physician documentation.
• K86.2 / K86.3 — Cyst/Pseudocyst: Assign in addition to the pancreatitis code when separately documented. Pancreatic pseudocysts may persist weeks after an acute episode and should appear on all relevant claims until resolved.
• Pancreatogenic diabetes: When a provider documents diabetes due to chronic pancreatitis, assign E08.x (Diabetes mellitus due to underlying condition) with an additional code for K86.0 or K86.1. The underlying condition (pancreatitis) sequences first per guidelines (ICD-10-CM FY2026 Section I.C.4).

SIRS and Organ Failure in Acute Pancreatitis

Per ICD-10-CM Section I.C.1.d, SIRS arising from a non-infectious cause (such as acute pancreatitis) is coded as:

• R65.10 — Systemic inflammatory response syndrome (SIRS) of non-infectious origin without acute organ dysfunction
• R65.11 — SIRS of non-infectious origin with acute organ dysfunction (code each organ failure additionally)

These codes should NOT be confused with sepsis codes (A41.x), which require a documented infection as the underlying cause. If the physician documents “sepsis” in the context of infected pancreatic necrosis, standard sepsis guidelines apply.

🔢 ICD-10-CM Code Set (FY2026)

All codes below are valid for FY2026 (October 1, 2025 – September 30, 2026) per CMS ICD-10-CM FY2026 release and CDC/NCHS Tabular List.

🔎 Indexing

The following index entries from the FY2026 ICD-10-CM Alphabetic Index are relevant for locating pancreatitis codes. Coders should use the index as the starting point, then verify in the Tabular List.

Note: The index term “pancreatitis, hemorrhagic” leads to K85.90. Coders should verify necrosis documentation in the record to upgrade to K85.x1 or K85.x2 as appropriate. “Necrotizing pancreatitis” is indexed to K85.91 (uninfected necrosis) by default; infected status requires explicit documentation to code K85.x2.

🏥 CPT (2026)

The following CY2026 CPT codes (AMA CPT® code set) are commonly used in pancreatitis management, ranging from diagnostic imaging and laboratory services to interventional and surgical procedures.

🧾 HCPCS (2026)

The following CY2026 HCPCS Level II codes are relevant to pancreatitis management, primarily covering pancreatic enzyme replacement products and related supplies.

📚 AHA Coding Clinic (Recent Guidance)

The following summarizes relevant guidance from the AHA Coding Clinic for ICD-10-CM/PCS. Coders and CDI specialists should always reference the most recent applicable Coding Clinic issue, as guidance supersedes prior editions.

💰 HCC / Risk Adjustment (v28)

The CMS-HCC Model V28 is fully operative for payment year 2026 (100% V28, as the phased implementation concluded). V28 replaced V24 entirely and is calibrated on ICD-10-CM codes, with significant changes to pancreatitis and related conditions.

*RAF weights are approximate based on CMS published V28 model coefficients. Actual weights vary by model segment (community/institutional, Medicaid/non-Medicaid, aged/disabled). Always verify with the most current CMS Rate Announcement and V28 Mappings file.

✍️ CDI Query Templates

All queries below conform to ACDIS and AHIMA standards: compliant, non-leading, multiple-choice format with a “clinically undetermined” option. Queries are for clarification purposes only and must be based on clinical evidence in the record.

🧑‍⚕️ Treatments (Clinical)

This section summarizes clinical treatment approaches as a reference for CDI specialists assessing clinical validity and for coders identifying procedure codes.

Acute Pancreatitis

• Fluid resuscitation: The cornerstone of AP management. Lactated Ringer’s solution is now preferred over normal saline based on multiple RCTs including the WATERFALL trial (NEJM, 2022), demonstrating reduced SIRS incidence. Goal-directed fluid therapy targeting urine output ≥0.5 ml/kg/hr is standard.
• Nutritional support: Oral feeding is resumed as soon as tolerated. For moderate-severe AP, early enteral nutrition via nasojejunal tube within 24–48 hours is preferred over TPN, per ACG Guidelines for AP Management.
• Pain management: Multimodal analgesia with IV opioids (hydromorphone, morphine); PCA in severe cases; epidural analgesia for refractory pain.
• Management of biliary pancreatitis: ERCP with sphincterotomy and stone extraction for choledocholithiasis-associated AP within 24–72 hours; cholecystectomy during same hospitalization or within 4 weeks for mild biliary AP to prevent recurrence.
• Infected necrotizing pancreatitis: Step-up approach preferred — percutaneous or endoscopic drainage as first step; open or minimally invasive necrosectomy (video-assisted retroperitoneal debridement, VARD) as escalation. PANTER trial (NEJM, 2010) established the step-up approach as superior to primary open necrosectomy.
• ICU management: Hemodynamic monitoring, vasopressors for shock (R57.1), mechanical ventilation for ARDS (J80), renal replacement therapy for AKI (N17.x).

Chronic Pancreatitis

• Pain management: Multimodal approach including analgesics, antidepressants (tricyclics, SNRIs), pregabalin, and endoscopic or surgical decompression. Celiac plexus block (CPT 64530) for refractory pain.
• Enzyme replacement (PERT): Pancrelipase (Creon, Zenpep, Viokace) 40,000–50,000 lipase units per meal and 20,000–25,000 lipase units per snack. PERT prescription documents EPI (K86.81) and supports outpatient CDI capture.
• Nutritional management: Fat-soluble vitamin supplementation (A, D, E, K); medium-chain triglyceride (MCT) supplementation; dietitian referral; alcohol and smoking cessation counseling.
• Management of pancreatogenic diabetes: Insulin therapy is typically required (beta cells lost); metformin with caution due to GI side effects; weight management critical.
• Endoscopic therapy: ERCP with ductal dilation, stenting (CPT 43274), stone extraction (CPT 43264), or extracorporeal shock wave lithotripsy (ESWL) for pancreatic duct stones.
• Surgical options:
  • Lateral pancreaticojejunostomy (Puestow procedure, CPT 48180): for dilated main pancreatic duct (>6–7mm) with chronic obstruction
  • Frey procedure (local resection of pancreatic head with lateral pancreaticojejunostomy): for CP with enlarged fibrotic head
  • Beger procedure (duodenum-preserving pancreatic head resection, CPT 48146)
  • Pancreaticoduodenectomy/Whipple (CPT 48150–48154): for end-stage disease, suspected malignancy, or failed prior surgical/endoscopic therapy
• Total pancreatectomy with islet autotransplantation (TPIAT): For refractory CP with intractable pain; preserves endocrine function via islet cell transplant to portal vein; performed at specialized centers.

🎓 Patient Education / Summary

This section provides a plain-language summary suitable for patient education materials and for helping clinical documentation specialists understand what patients are experiencing — context that informs effective CDI conversations with providers.

What Is Pancreatitis?

The pancreas is a gland behind the stomach that makes digestive juices and hormones including insulin. Pancreatitis means the pancreas is inflamed. In acute pancreatitis, it becomes suddenly inflamed and usually gets better with treatment over days to weeks. In chronic pancreatitis, long-term damage causes scarring and the pancreas gradually loses its ability to digest food and control blood sugar.

Common Causes

• Gallstones are the #1 cause of acute pancreatitis in the United States — a stone blocks the bile duct where it meets the pancreatic duct, triggering inflammation
• Heavy alcohol use is the leading cause of chronic pancreatitis and a major cause of acute pancreatitis
• Medications (some diuretics, antibiotics, chemotherapy drugs)
• Very high triglycerides in the blood
• Genetic factors (hereditary pancreatitis) in younger patients

What Patients Should Know

• Most acute pancreatitis cases (about 80%) are mild and recover fully with IV fluids and bowel rest
• Severe pancreatitis can be life-threatening and may require ICU care, surgery, or weeks in hospital
• If pancreatitis is caused by gallstones, removing the gallbladder prevents future attacks
• Stopping alcohol use completely is the single most important step in preventing chronic pancreatitis from worsening
• If the pancreas stops making enough digestive enzymes (exocrine pancreatic insufficiency), prescription enzyme capsules (taken with every meal and snack) can restore normal digestion and prevent malnutrition
• Chronic pancreatitis can cause diabetes that requires insulin — regular endocrine follow-up is essential
• Smoking dramatically worsens chronic pancreatitis and should be stopped
• A low-fat diet reduces symptoms; a registered dietitian referral is recommended for all chronic pancreatitis patients

CDI Takeaway for Documentation Specialists

When reviewing records for patients with pancreatitis, ensure the provider has clearly documented: (1) etiology of the pancreatitis (gallstone, alcohol, drug, other), (2) severity and necrosis status for acute cases, (3) whether pancreatitis is acute, chronic, or acute-on-chronic, (4) any complications including EPI, pancreatogenic diabetes, pseudocyst, SIRS, or organ failure. Clear, specific documentation not only optimizes reimbursement and risk adjustment but most importantly reflects the true clinical complexity of these patients — supporting quality metrics, readmission risk stratification, and longitudinal care planning. For further coding education, visit CCO — Coding, Certification, and Compliance.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)